II. Indications
- Refractory Vasomotor Symptoms of Menopause (Hot Flashes)
- Second-line option when hormonal therapy is contraindicated
III. Contraindications
- Cirrhosis
- Severe renal Impairment (including end-stage renal disease)
IV. Mechanism
- Neurokinin 3 Receptor Antagonist
- Small molecule NK3 Receptor Antagonist
- Blocks neurokinin B (NKB) at the infundibular nucleus of the Hypothalamus
- Neurokinin B (NKB) regulates temperarture
- Blockade can decrease Vasomotor Symptoms of Menopause (Hot Flashes)
V. Medications
- Fezolinetant (Veozah)
- Cost: $550 per month when released in 2023
VI. Dosing
- Fezolinetant (Veozah) 45 mg orally daily (with or without food)
- Obtain baseline hepatic panel prior to starting, then in 3, 6 and 9 months
- Stop periodically to assess continued need
VII. Adverse Effects
VIII. Efficacy
- Fezolinetant 45 mg daily reduces Hot Flashes by 2 to 3 per day
- Less effective than hormonal therapy for Vasomotor Symptoms of Menopause
- Similar to SNRIs, SSRIs and Gabapentin in hot flash reduction
- Was not studied in women age >65 years prior to release
IX. Drug Interactions
-
CYP1A2 Inhibitors (e.g. Allopurinol, Omeprazole, Fluvoxamine, Cimetidine)
- Increase Fezolinetant levels
X. Resources
Images: Related links to external sites (from Bing)
Related Studies
| veozah (on 9/20/2023 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| VEOZAH 45 MG TABLET | $17.53 each | |